Y-mAbs Therapeutics, Inc.

Equities

YMAB

US9842411095

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
11.6 ^USD	-2.11%		-5.54%	+70.09%

08/05	Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
07/05	Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M	MT

Y-mAbs Therapeutics, Inc. Announces Resignation of Gérard Ber, Ph.D. from the Board of Directors, Effective June 10, 2024

April 30, 2024 at 02:39 am IST

Y-mAbs Therapeutics, Inc. announced that on April 25, 2024, Gérard Ber, Ph.D., notified the company that he would be resigning from the Board of Directors of the Company, with such resignation to be effective on June 10, 2024, the day before the date set for the Company?s 2024 annual meeting of stockholders. Dr. Ber?s resignation is not due to any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.

Latest news about Y-mAbs Therapeutics, Inc.

Transcript : Y-mAbs Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Posts Q1 Revenue $19.9M, vs. Street Est of $22.2M	08/05	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Y-mAbs Therapeutics, Inc. Announces Resignation of Gérard Ber, Ph.D. from the Board of Directors, Effective June 10, 2024	30/04	CI
Y-mAbs Therapeutics Chief Financial Officer Bo Kruse to Resign	14/03	MT
Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024	14/03	CI
Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer	14/03	CI
HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating	06/03	MT
Canaccord Genuity Raises Price Target on Y-mAbs Therapeutics to $26 From $22, Maintains Buy Rating	04/03	MT
BMO Capital Adjusts Y-mAbs Therapeutics Price Target to $26 From $16, Maintains Outperform Rating	04/03	MT
Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors	04/03	CI
Wedbush Raises Y-mAbs Therapeutics' PT to $23 From $18 After Higher-Than-Expected Q4 2023 Danyelza Net Product Revenue, Maintains Outperform Rating	04/03	MT
Transcript : Y-mAbs Therapeutics, Inc., Q4 2023 Earnings Call, Mar 01, 2024	01/03
Y-mAbs Therapeutics Surges 18% in Premarket Activity Following Q4 Results; Reiterates Anticipated Cash Runway into 2027	01/03	MT
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03	CI
Earnings Flash (YMAB) Y-MABS THERAPEUTICS Reports Q4 Revenue $23.4M, vs. Street Est of $21M	01/03	MT
Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	01/03	CI
Y-mAbs Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03	CI
HC Wainwright Adjusts Y-mAbs Therapeutics Price Target to $21 From $11, Maintains Buy Rating	20/02	MT
Wedbush Raises Price Target on Y-mAbs Therapeutics to $18 From $12 After Plans for Phase 1 Cancer Drug Study, Keeps Outperform Rating	12/02	MT
Transcript : Y-mAbs Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	11/01
Kempen Upgrades Y-mAbs Therapeutics to Buy From Neutral, Price Target is $10	22/12	MT
Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) added to NASDAQ Biotechnology Index	18/12	CI
Y-mAbs Therapeutics to Join NASDAQ Biotechnology Index Dec. 18	14/12	MT
Y-mabs Therapeutics Insider Bought Shares Worth $521,294, According to a Recent SEC Filing	30/11	MT

Chart Y-mAbs Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.

Sector

Biotechnology & Medical Research

Calendar

31/05/2024 - American Society of Clinical Oncology Annual Meeting - Poster Number: #10037

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Y-mAbs Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.6 USD

Average target price

21.33 USD

Spread / Average Target

+83.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
Y-MABS THERAPEUTICS, INC.	+70.09%	51Cr
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.84%	11TCr
ARGENX SE	-1.05%	2.2TCr
BIONTECH SE	-14.15%	2.19TCr
GENMAB A/S	-5.29%	1.92TCr
BEIGENE, LTD.	-4.16%	1.81TCr
WUXI APPTEC CO., LTD.	-38.29%	1.77TCr
NEUROCRINE BIOSCIENCES, INC.	+7.99%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+36.24%	1.24TCr

Bio Therapeutic Drugs